Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies

Social Science and Medicine

Volumn 70, Issue 5, 2010, Pages 643-647

  Lexchin, Joel ^b,c,d   O'Donovan, Orla ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Conflict of interest; Drug regulation; European Union; Ireland; Risk management; UK

Indexed keywords

CONFLICT MANAGEMENT; DECISION MAKING; DRUG; EUROPEAN UNION; MEDICINE; PHARMACEUTICAL INDUSTRY; POLICY ANALYSIS; REGULATORY FRAMEWORK; RISK ASSESSMENT;

ACCESS TO INFORMATION; ADVISORY COMMITTEE; ARTICLE; CONFLICT OF INTEREST; DRUG CONTROL; EUROPEAN UNION; GOVERNMENT REGULATION; IRELAND; LAW; MEDICAL ETHICS; RISK MANAGEMENT; UNITED KINGDOM;

CONFLICT OF INTEREST; DECISION MAKING, ORGANIZATIONAL; DRUG AND NARCOTIC CONTROL; EUROPEAN UNION; GOVERNMENT AGENCIES; GOVERNMENT REGULATION; GREAT BRITAIN; HUMANS; IRELAND; ORGANIZATIONAL POLICY;

IRELAND; UNITED KINGDOM;

EID: 75849154974     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2009.09.002     Document Type: Article

References (27)

1. Abraham J. Science, politics and the pharmaceutical industry (1995), UCL Press, London
2. Abraham J. From evidence to theory - neo-liberal corporate bias as a framework for understanding UK pharmaceuticals regulation. Social Theory and Health 5 (2007) 161-175
3. Abraham J. Sociology of pharmaceutical development and regulation: a realist empirical research programme. Sociology of Health and Illness 30 6 (2008) 869-885
4. Abraham J., and Lewis G. Regulating medicines in Europe: Competition, expertise and public health (2000), Routledge, London
5. Abraham J., and Reed T. Trading risks for market: the international harmonisation of pharmaceuticals regulation. Health, Risk & Society 3 (2001) 113-128
6. Abraham J., and Sheppard J. The therapeutic nightmare: The battle over the world's most controversial sleeping pill (1999), Earthscan, London
7. Bero L., Oostvogel F., Bacchetti P., and Lee K. Factors association with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Medicine 4 6 (2007) e184
8. Borgert C. Conflict of interest or contravention of science?. Regulatory Toxicology and Pharmacology 48 (2007) 4-5
9. De Vries R., and Bosk C. The bioethics of business: rethinking the relationship between bioethics consultants and corporate clients. Hastings Centre Report 34 5 (2004) 28-32
10. Dukes M.N.G. The effects of drug regulation: A survey based on the European studies of drug regulation (1985), MTP Press, Lancaster
11. Epstein R. Overdose. How excessive government regulation stifles pharmaceutical innovation (2006), Yale University Press, New Haven
12. European Medicines Agency. EMEA procedure on the handling of conflicts of interests for EMEA scientific committees members and EMEA experts (2006). http://www.emea.europa.eu/pdfs/general/direct/conflicts/ProcedureHandlingofConflictsofInterests.pdf [online] Retrieved February 13, 2009
13. European Medicines Agency. Declaration of Interests Assessment Group: rules of procedure (2006). http://www.emea.europa.eu/pdfs/general/direct/conflicts/Annex4-RulesofProcedure.pdf [online] Retrieved February 13, 2009
14. Healy D. Let them eat Prozac: The unhealthy relationship between the pharmaceutical industry and depression (2004), New York University Press, New York
15. Jasanoff S. Designs on nature. Science and democracy in Europe and the United States (2005), Princeton University Press, Princeton
16. Kassirer J. Medicine's obsession with disclosure of financial conflicts: fixing the wrong problem. In: Snyder P.J., Mayes L.C., and Spencer D.D. (Eds). Science and the media: Delgado's brave bulls and the ethics of scientific disclosure (2008), Academic Press
17. Kirby P. The Irish state and the Celtic Tiger: a 'flexible developmental state' or a competition state?. In: Harrison G. (Ed). Global encounters: International political economy, development and globalisation (2005), Palgrave/Macmillan, London 74-94
18. Krimsky S. Science in the private interest: Has the lure of profits corrupted biomedical research? (2003), Rowman & Littlefield, New York
19. Levidow L. Precautionary uncertainty: regulating GM crops in Europe. Social Studies of Science 31 6 (2001) 842-874
20. Lexchin J., Bero L., Djubegovic B., and Clark O. Pharmaceutical industry sponsored research: evidence for a systematic bias. BMJ 326 (2003) 1167-1170
21. Lurie P., Almeida C.M., Stine N., Stine A.R., and Wolfe S.M. Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings. JAMA 295 (2006) 1921-1928
22. Medicines Act 1968 Advisory Bodies: Annual reports 2006 (2007), Medicines and Healthcare Products Regulatory Agency, London. http://www.pharmacopoeia.gov.uk/custom/files/M%20Act%201968%20Adv%20Bodies%20Annual%20Report%202006.pdf
23. Mossialos E., Mrazek M., and Walley T. Regulating pharmaceuticals in Europe: Striving for efficiency, equity and quality (2004), Open University Press, Maidenhead
24. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (2004). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: L:2004:136:0001:0033:EN:PDF [online] Retrieved February 13, 2009
25. Scott J.C. Seeing like a state. How certain schemes to improve the human condition have failed (1998), Yale University Press, New Haven
26. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Social Science & Medicine 66 (2008) 1909-1914
27. Stark A. Conflict of interest in American public life (2003), Harvard University Press, Cambridge, Mass